HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of ifosfamide in the treatment of sarcomas.

Abstract
The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas. In advanced soft tissue sarcomas, doxorubicin and ifosfamide are the most active single agents. Their combination results in response rates of 34% to 41% in various trials. In advanced osteosarcoma and Ewing's sarcoma, ifosfamide also is active. In Ewing's sarcoma, the above combination with etoposide has resulted in high response rates.
AuthorsL Y Dirix, A T Van Oosterom
JournalSeminars in oncology (Semin Oncol) Vol. 16 Issue 1 Suppl 3 Pg. 39-45 (Feb 1989) ISSN: 0093-7754 [Print] United States
PMID2649984 (Publication Type: Journal Article, Review)
Chemical References
  • Ifosfamide
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Humans
  • Ifosfamide (administration & dosage, therapeutic use)
  • Osteosarcoma (drug therapy)
  • Sarcoma (drug therapy)
  • Sarcoma, Ewing (drug therapy)
  • Soft Tissue Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: